Clinical Characterization of Use of Acamprosate and Naltrexone: Data from an Addiction Center in India

REFERENCES

• Hughes JC, Cook CCH. The efficacy of disulfiram: a review of outcome studies. Addiction. 1997;92:381–395. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Malley SS, Jaffe AJ, Chang G, ., et al. Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry. 1992;49:881–887. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Alterman AI, Hayashida M, ., et al. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry. 1992;49:876–880. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drug approval–naltrexone. Available at http://www.fda.gov/cder/foi/nda/99/75274_Naltrexone.pdf. Accessed May 26, 1999.
   Google Scholar
• O'Malley SS, Jaffe AJ, Chang G, ., et al. Six month follow up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry. 1996;53:217–224. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Volpicelli JR, Rhines KC, Rhines JS, ., et al. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry. 1997;54:737–742. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Boismare F, Daoust M, Moore N, ., et al. A homotaurine derivative reduces the voluntary intake of ethanol by rats: are cerebral GABA receptors involved? Pharmacol Biochem Behav. 1984;21:787–789. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Lhuintre JP, Daoust M, Moore ND, ., et al. Ability of calcium bis-acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 1985;1(8436):1014–1016. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lhuintre JP, Moore N, Tran G, ., et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25:613–622. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Paille FM, Guelfi JD, Perkins AC, ., et al. Double-blind randomized multi-center trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239–247. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Whitworth AB, Fischer F, Lesch OM, ., et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347(9013):1438–1442. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, ., et al. Relapse prevention by acamprosate: results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673–680. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pelc I, Verbanck P, LeBon O, ., et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients: a 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171:73–77. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Overman GP, Teter CJ, Guthrie SK. Acamprosate for the adjunctive treatment of alcohol dependence. Ann Pharmacotherapy. 2003;37:1090–1099. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Mason BJ. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001;62(suppl 20):42–48. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Graham R, Wodak AD, Whelan G. New pharmacotherapies for alcohol dependence. Med J Australia. 2002;177:103–107. [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335–1341. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• UNDCP-ROSA. Country Profile—India. In: Ray R, ed. South East Asia Drug Demand Reduction Report. New Delhi: UNDCP Regional Office for South Asia; 1998:259–261.
   Google Scholar
• World Health Organization. Global Alcohol Status Report: the South-East Asia Region. Available at: http://www.who.int/substance_abuse/PDFfiles/global_alcohol_status_report/TheSouth-EastAsiaRegiontest.pdf. Accessed on 23 Jan 2001.
   Google Scholar
• Moncrieff J, Drummond DC. New drug treatments for alcohol problems: a critical appraisal. Addiction. 1997;92:939–947. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chick J, Howlett H, Morgan MY, ., et al. United Kingdom Multi-center Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176–187. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Namkoong K, Lee BO, Lee PG, ., et al. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003;38:135–141. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2002;2:CD001867. [PUBMED], [INFOTRIEVE], [CSA]
   Google Scholar
• Rubio G, Jimenez-Arriero MA, Ponce G. Naltrexone versus acamprosate: one-year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001;36:419–425. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kiefer F, Jahn H, Tarnaske T, ., et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003;60:92–99. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions for alcohol dependence (the COMBINE study): a pilot feasibility study. Alcohol Clin Exp Res. 2003;27:1123–1131. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• World Health Organization. The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Description & Diagnostic Guidelines. Geneva: WHO; 1992.
   Google Scholar
• Chick J. Pitfalls and possibilities in evaluating pharmacotherapies for alcohol dependence. Addiction. 1997;92:953–956. [CSA]
   Web of Science ®Google Scholar
• SPSS Inc. Statistical Package for the Social Sciences, 10th ed. Charlottesville, NJ: SPSS, Incorporated; 1999.
   Google Scholar
• Wilde MI, Wagstaff AJ. Acamprosate: a review of its pharmacology and clinical potential in the management of alcohol dependence after detoxification. Drugs. 1997;53:1038–1053. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Pelc I, Ansoms C, Lehert P, ., et al. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction. Alcohol Clinl Exp Res. 2002;26:1529–1538. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Littleton J. Acamprosate in alcohol dependence: how does it work? Addiction. 1995;90:1179–1188. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Weinstein A, Feldtkeller B, Feeney A, ., et al. A pilot study on the effects of treatment with acamprosate on craving for alcohol in alcohol-dependent patients. Addict Biol. 2003;8:229–232. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Guscott R, Taylor L. Lithium prophylaxis in recurrent affective illness: efficacy, effectiveness, and efficiency. Br J Psychiatry. 1994;164:741–746. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Feeney GF, Young RM, Connor JP, ., et al. Cognitive behavioural therapy combined with the relapse-prevention medication acamprosate: are short-term treatment outcomes for alcohol dependence improved? Aust NZ J Psychiatry. 2002;36:622–628. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Soyka M, Preuss U, Schuetz C. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism: results from a non-blind, multicentre study. Drug Dev Res. 2002;3:1–12. [CSA]
   Google Scholar
• De Wildt WA, Schippers GM, Van Den Brink W, ., et al. Does psychosocial treatment enhance the efficacy of acamprosate in patients with alcohol problems? Alcohol Alcohol. 2002;37:375–382. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• COMBINE Study Research Group. Testing combined pharmacotherapies and behavioral interventions in alcohol dependence: rationale and methods. Alcohol Clin Exp Res. 2003;27:1107–1122. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar